FDA Investigator Wei Wang, PhD
Wei Wang, PhD has inspections in 2 countries as of 01 Sep 2023. Wei Wang, PhD has collaborated with a combinined 2667 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
12
Last Inspection Date:
01 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America,
United Kingdom of Great Britain and Northern Ireland
Co-Investigator(s):
Alberto A Viciedo,
Alla Kachko, PhD,
Anastasia I Offordile,
Andrew Byrnes, PhD,
Angela S Whatley,
Anissa M Cheung,
Anita R Michael,
Ann L Demarco,
Ann Marie Montemurro,
Ann Marie Schofield,
Anna R Kwilas,
Arie C Menachem,
Audrey Thereset Uy,
Barbara M Frazier,
Bo Liang, PhD,
Bradley Dworak, PhD,
Brentley S Collins,
Brian S Keefer,
Burnell M Henry,
Carl A Perez,
CDR Donald Ertel,
CDR Jeremy L Wally, PhD,
Chao Ming Tsai,
Christian D Lynch (CDL),
Christina J Sauder, PhD,
Christine A Harman, PhD,
Christopher J Adams,
Craig D Zagata,
Cynthia Jim, CSO,
Daniel C Kearns,
Dave Hafner,
David J Hafner,
Deborah M Trout,
Debra J Bennett,
Debra L Pagano,
Destry M Sillivan,
Devaughn Edwards,
Dino Feigelstock (DF), PhD,
Douglas C Kovace,
Douglas C Kovacs,
Dr. Gang Wang, PhD,
Dr. Willie F Vann, PhD,
Edmund F Mrak, Jr,
Edmund Fmrakjr S,
Eileen A Liu,
Eliezar Ramos,
Ellen Huang,
Eric J Cunningham,
Frank J Marciniak,
Gene D Arcy,
Graeme E Price,
Graeme Price,
Hala L Selby,
Haruhiko Murata,
Helen B Ricalde,
J David Doleski,
Jacqueline Mdiaz Albertini,
Jakob Reiser, PhD,
James E Keller, PhD,
James M Mason,
James R Evans,
Jennifer L Schmidt,
Jianyang Wang,
Joan A Loreng,
Joan Adamo,
Joanne M Hajoway,
Jogy George,
Jose M Cayuela,
Joseph George,
Julianne C Mccullough,
Julie D Bringger,
Junho Pak,
Justin A Boyd,
Karen E D'orazio,
Karyn M Campbell,
Kathleen B Mihalik,
Kathryn Carbone, MD,
Kelly N Kerr,
Kenneth M Gordon,
Kinh Q Mac,
Kristen D Evans,
Kula N Jha,
Laurel A Beer,
Lauren M Lilly, PhD,
Laurie P Norwood,
LCDR Margaret E Digennaro,
Lewis K Antwi,
Li Li,
Linda Thai,
Lisa Feela,
Lisa M Bellows,
LT John M Mastalski,
Marian E Major, PhD,
Marion Michaelis,
Mariza M Jafary,
Melba T Rivera,
Melba Trivera Clavell,
Melissa A Zuppe,
Michael Curbag,
Michael Gurbarg,
Michael Havert, PhD,
Michael R Klapal,
Michele L Forster, PhD,
Mihaly S Ligmond,
Nicole K Trudel,
Nikisha M Bolden,
Nikki S Ramirez,
Omotunde O Osunsanmi,
Paula A Trost,
Prabhu P Raju,
Pratik S Upadhyay, DDC,
Priscilla M Pastrana,
Ralph A Erickson,
Ramon E Martinez,
Rebecca K Olin,
Richard Heath Coats,
Richard W Thornton,
Robert B Shibuya, MD,
Robert C Coleman,
Robert D Tollefsen,
Robert G Ruff,
Robert Sausville,
Robert W Jennings,
Rose M Ashley,
Sarah B Tanksley,
Scott E Norris,
Scott T Ballard,
Sean R Bryd,
Sheila Dreher Lesnick,
Sherry G Bous,
Shuang Tang,
Sidney B Priesmeyer,
Simone E Pitts,
Solomon Yimam (SY),
Stephanie Mangigian, MS/OSH, RN,
Stephen D Brown,
Steven A Rubin,
Steven E Bowen, PhD,
Susan F Laska, MS,
Susan M Jackson,
Tammy L Chavis,
Thomas J Arista,
Tina S Roecklein,
Vlada Matusovsky,
Wei Wanet,
Xiao Wang,
Xiuju Lu,
Yonggang Wang, PhD,
Yvesna C Blaise,
Zakaria I Ganiyu
Wei Wang, PhD's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| June, 2017 | FDA 483 Response | KITE PHARMA, INC. - Form 483R, 2017-06-29 |
| February, 2013 | FDA 483 | Merck Sharp & Dohme LLC - Form 483, 2013-02-06 |
| February, 2018 | FDA 483 | Symbiosis Pharmaceutical Services Limited - Form 483, 2018-02-23 |
| June, 2017 | EIR | KITE PHARMA, INC. - EIR, 2017-06-16 |
| June, 2017 | FDA 483 | SAFC Carlsbad Inc. - Form 483, 2017-06-22 |
| May, 2014 | FDA 483 | Sanofi Pasteur Inc. - Form 483, 2014-05-09 |
| February, 2019 | FDA 483 | Novartis Gene Therapies, Inc. - Form 483, 2019-02-08 |
| June, 2017 | FDA 483 | KITE PHARMA, INC. - Form 483, 2017-06-16 |
| May, 2014 | EIR | Sanofi Pasteur Inc. - EIR, 2014-05-09 |
| February, 2019 | FDA 483 Response | Novartis Gene Therapies, Inc. - Form 483R, 2019-03-12 |
Experience Redica System's NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more